// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone (A) and docetaxel (D).

Shruti Parshad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Daniel J. George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

Celestia S. Higano - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.

Ronan Le Moigne - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

Dissecting the expression landscape of genitourinary cancers.

Claudio Jeldres - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).

Daniel W. Lin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.

Disharee Nath - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

The association between physician trust and prostate specific antigen screening: Implications for shared decision making.

Zachary William Abraham Klaassen - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).

Jean-Michel Lavoie - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adrenal carcinoma

N/A

Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).

Tamim Niazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Arjun Vasant Balar - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Pembrolizumab

Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.

Lucia Nappi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Impact of a geriatric oncology (GO) clinic on cancer treatment plans and supportive care for older adults with genitourinary (GU) cancer.

Shabbir M.H. Alibhai - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Radiogenomic characterization of multifocal prostate cancer.

Simpa Samuel Salami - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.

Tatsuya Shimomura - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.

Gregory Russell Pond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Atezolizumab

Evaluation of PUMA and NOXA expression as predictive biomarkers in prostate cancer.

Sylvie Clairefond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

Jason J. Luke - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Nivolumab

Correlation of MTOR protein expression in the tumor and its microenvironment with more aggressive pathology at cystectomy.

Brian Winters - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).

Jacob A Gordon - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Copyright © 2026. QuantiNova All rights reserved